Table 3: Univariate analysis on disease-free survival.
|
Variable |
n (%) |
Median DFS in months |
3y-DFS |
5y-DFS |
p |
|
Whole cohort |
85 (100) |
27 |
40% |
20% |
|
|
Gender M F |
52 (61.2) 33 (38.8) |
37 19 |
53% 21% |
36% NA |
0.057 |
|
SCC Non-squamous |
30 (35.3) 55 (64.7) |
37 25 |
55% 30% |
38% NA |
0.25 |
|
Lobectomy/Sublobar Pneumonectomy |
67 (78.8) 14 (16.5) |
29 25 |
46% 29% |
22% NA |
0.66 |
|
Clinical stage IIIA IIIB |
63 (74.1) 22 (25.9) |
28 16 |
42.5% 33.5% |
NA 22% |
0.25 |
|
RECIST response CR+PR SD |
57 (67) 28 (33) |
27 29 |
44% 34% |
39% NA |
0.27 |
|
Downstaged ypN2 |
58 (68.2) 27 (37.8) |
32 28 |
46% 25% |
37% NA |
0.039 |
|
LNR0 LNR<0.29 LNR>0.29 |
44 (51.8) 28 (32.9) 13 (15.3) |
27 41 15 |
44% 59% 14% |
38% NA NA |
0vs<0.29 0.98 0vs>0.29 0.043 <0.29vs>0.29 0.03 |
|
ypN+ <0.29 ypN+ >0.29 |
28 (32.9) 13 (15.3) |
41 15 |
62% 14% |
NA NA |
0.03 |
|
N0+N1+N2 LNR <0.29 LNR >0.29 |
72 (84.7) 13 (15.3) |
27 15 |
46% 14% |
25% NA |
0.022 |
|
ypN1<0.29 ypN2<0.29 |
14 (16.5) 14 (16.5) |
41 54 |
64% 63% |
NA NA |
0.82
|
|
ypN0+N1<0.29 ypN2<0.29 |
58 (68.2) 14 (16.4) |
32 54 |
46% 63% |
37% NA |
0.48 |
|
Resection status R0 R1 |
70 (82.3%) 15 (17.7%) |
28 15 |
42.5% 37.5% |
23% NA |
0.025 |
|
PORT No treatment Yes |
43 (50.6) 4 (4.7) |
54 18 |
54% 25% |
36% NA |
0.15 |
|
Adjuvant chemotherapy No treatment Yes |
43 (50.6) 29 (34.1) |
54 28 |
54% 34% |
36% NA |
0.16 |
|
Adjuvant CHT+RT No treatment Yes |
43 (50.6) 9 (10.5) |
54 25 |
54% 37% |
36% NA |
0.18 |
|
Multistation ypN2 No yes |
13 (15.3) 14 (16.5) |
15 15 |
24.5% 24% |
NA NA |
0.45 |
DFS: Disease-Free Survival; NA: Not Available; SCC: Squamous Cell
Carcinoma; RECIST: Response Evaluation Criteria in Solid Tumors; CR: Complete
Response; PR: Partial Response; SD: Stable Disease; LNR: Lymph Node Ratio;
PORT: Post-Operative Radiotherapy; CHT: Chemotherapy; RT: Radiation Therapy.